BNOX vs. VIRI, CYCN, CVKD, TRVN, NCNA, VCNX, EFTR, BFRI, HEPA, and UPC
Should you be buying Bionomics stock or one of its competitors? The main competitors of Bionomics include Virios Therapeutics (VIRI), Cyclerion Therapeutics (CYCN), Cadrenal Therapeutics (CVKD), Trevena (TRVN), NuCana (NCNA), Vaccinex (VCNX), eFFECTOR Therapeutics (EFTR), Biofrontera (BFRI), Hepion Pharmaceuticals (HEPA), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical preparations" industry.
Bionomics (NASDAQ:BNOX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.
Bionomics received 14 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 72.73% of users gave Bionomics an outperform vote while only 66.67% of users gave Virios Therapeutics an outperform vote.
Bionomics currently has a consensus target price of $9.00, indicating a potential upside of 836.23%. Given Bionomics' higher probable upside, research analysts clearly believe Bionomics is more favorable than Virios Therapeutics.
Bionomics' return on equity of 0.00% beat Virios Therapeutics' return on equity.
In the previous week, Virios Therapeutics had 4 more articles in the media than Bionomics. MarketBeat recorded 4 mentions for Virios Therapeutics and 0 mentions for Bionomics. Bionomics' average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.
Bionomics has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.
Virios Therapeutics has lower revenue, but higher earnings than Bionomics.
15.9% of Bionomics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 1.5% of Bionomics shares are owned by insiders. Comparatively, 11.7% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Bionomics beats Virios Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Bionomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionomics Competitors List
Related Companies and Tools
